Evolving therapeutic approaches in late-onset genetic cholestasis
Carola Dröge and Verena Keitel-Anselmino discuss IBAT inhibitor therapy in adults with hereditary BSEP-deficiency at EASL 2026.
Observational data show IBAT inhibitor promise for pruritus in late-onset PFIC and ICP
Real-world data show promise for IBAT inhibitor use in adults with late-onset PFIC and women with ICP.
Intrahepatic cholestasis of pregnancy recurs in 4 in 10 pregnancies
Researchers evaluate the incidence of intrahepatic cholestasis of pregnancy recurrence and identify potential predictors.
Case series suggests IBAT inhibitor benefits in adults with hereditary BSEP deficiency
Clinical data suggest comparable IBAT inhibitor response for adults with hereditary BSEP deficiency as seen in pediatric trials.
AASLD 2025 Reflections: Key takeaways in primary sclerosing cholangitis
Dr Marlyn Mayo and Dr Andreas Kremer share key insights on primary sclerosing cholangitis from AASLD The Liver Meeting 2025, and explore the latest in therapeutic developments and symptomatology.
AASLD 2025 Reflections: Key takeaways in late-onset genetic cholestasis
Dr Silvia Vilarinho and Dr Deepak Joshi share the highlights from AASLD The Liver Meeting 2025, with an emphasis on late-onset genetic cholestasis, and offer quick insights into new data on the growing utility of genetic testing and expanding therapeutic implications.
AASLD 2025 Reflections: Key takeaways in primary biliary cholangitis
Dr Andreas Kremer and Dr Marlyn Mayo highlight key advances in primary biliary cholangitis from AASLD The Liver Meeting 2025, and provide quick insights into the latest data on next-generation therapies.
Seladelpar improves wellbeing and lowers itch impact
Marlyn Mayo reviews RESPONSE analyses on seladelpar symptom effects in PBC.
Survey reveals limitations to pruritus assessment in PSC
Marlyn Mayo discusses findings on physician attitudes to managing pruritus in PSC.
Ongoing seladelpar treatment continues to benefit PBC patients
Giving seladelpar beyond 12 months offers primary biliary cholangitis patients improvements in pruritus and biochemical markers, show ongoing analyses.
Maralixibat offers clinically meaningful pruritus reductions in PSC
A real-world analysis of PSC patients given maralixibat suggests it offers meaningful improvements in pruritus.
Volixibat improves fatigue and sleep in PBC alongside pruritus
An analysis of trial data indicates that, alongside reducing pruritus, volixibat helps normalize fatigue and sleep in PBC patients.
Novel panel identifies variants in unexplained cholestatic cases
A large US gene panel has helped to elucidate the underlying genetic basis of unexplained cholestasis.
Gene mutations linked to adult cholestasis
Mitchell Shiffman discusses the value of genetic testing in adults with undefined cholestasis.
Sustained responses to elafibranor in PSC
Mitchell Shiffman comments on ELMWOOD findings for elafibranor in PSC.
Long-term elafibranor therapy improves PBC outcomes
ELATIVE open-label extension trial findings support long-term elafibranor treatment in patients with PBC.
Distressing PSC symptoms fit profiles that could guide treatment
US researchers have found that the numerous and potentially distressing symptoms of PSC fit into four clear profiles.
ELATIVE: Sustained elafibranor benefit and biomarker potential
Mark Swain on 3-year elafibranor benefits, proteomics in PBC.
Seladelpar cholestasis benefits extend long term
Discussing the ASSURE findings for seladelpar in PBC with Daniel Pratt.
Pharmacodynamic findings support linerixibat pruritus benefits in patients with PBC
Andreas Kremer explains post-hoc analysis findings from the phase 3 GLISTEN trial showing an effect of linerixibat on biomarkers and mediators of pruritus in patients with PBC.
NLP medical review may help identify adults with undiagnosed PFIC
Natural language programming could help identify which adults with cholestasis have late-onset progressive familial intrahepatic cholestasis.
IBAT inhibitors may improve post-liver transplant pruritus
Treatment-refractory pruritus following liver transplant may be successfully treated with IBAT inhibitors, suggests a US case series.
Responses to elafibranor in primary sclerosing cholangitis maintained after initial treatment
An open-label trial extension showed that the PPAR agonist elafibranor maintained efficacy, and former placebo patients saw improvements.
Contraceptives linked to unique cholestatic phenotype
Raj Vuppalanchi reports findings characterizing the phenotype of women with hormonal contraceptive-associated drug-induced liver injury.
Elafibranor improves symptom burden, unaffected by BMI
Andreas Kremer discusses post-hoc analyses from the ELATIVE trial showing independent improvement in patient-reported outcomes with elafibranor for patients with PBC and efficacy irrespective of BMI.
Countdown to AASLD 2025: A preview with Marlyn Mayo and Andreas Kremer
Dr Marlyn Mayo and Dr Andreas Kremer discuss what’s ahead at AASLD 2025, with a focus on advances in primary biliary cholangitis and primary sclerosing cholangitis. They share their perspectives on emerging research, key topics to watch, and what they are most looking forward to at this year’s meeting.
Countdown to AASLD 2025: A preview with Marlyn Mayo and Andreas Kremer
Dr Marlyn Mayo and Dr Andreas Kremer discuss what’s ahead at AASLD 2025, with a focus on advances in primary biliary cholangitis and primary sclerosing cholangitis. They share their perspectives on emerging research, key topics to watch, and what they are most looking forward to at this year’s meeting.
IBAT inhibitor case studies point to adult intrahepatic cholestasis benefits
Ileal bile acid transporter inhibitors help treat adults with drug-induced or pregnancy-related intrahepatic cholestasis
Diagnosing and managing late-onset genetic cholestasis: a clinical pathway tool
A practical algorithm tool to help you navigate the different clinical presentations, reach an accurate diagnosis, and take optimal first management steps.
Updates on IBAT inhibitors from EASL 2025
Dr Richard Thompson and Dr Verena Keitel-Anselmino discuss the latest updates on IBAT inhibitors from EASL 2025, including their potential use in PBC patients based on promising phase I and II trial results.
EASL guidelines offer ‘framework’ for intrahepatic cholestasis of pregnancy care
Research confirms that the EASL guidelines aid risk stratification for intrahepatic cholestasis of pregnancy.
ABCB4 variant genotype–phenotype relationship in cholestasis elucidated
Research sheds light on the varying impact of ABCB4 gene variants in intrahepatic cholestasis of pregnancy and other adult-onset forms of cholestasis.
Odevixibat update for adult PFIC, older Alagille syndrome patients
Updated results for adult participants of the PEDFIC2 trial and older children taking part in the ASSERT-EXT study.
Genetic analysis aids diagnosis for atypical PFIC presentation
Case studies demonstrate the utility of genetic analysis and whole-exome sequencing for the diagnosis of progressive familial intrahepatic cholestasis in patients with nonspecific liver disease.
Unmet needs in late-onset genetic cholestasis: an expert discussion
This CME-accredited expert discussion aims to highlight the unmet needs in late-onset genetic cholestasis and provide guidance on the use of genetic testing in the diagnostic workup and initial management steps for the different genotypes, with reference to key trials and updates from The Liver Meeting 2024: American Association for the Study of Liver Diseases (AASLD).
Comprehensive PBC management: innovative and personalized plans to enhance patient outcomes
Led by Emma Culver, this interactive case study follows a 40-year-old woman who is referred to the clinic following profound fatigue, and discusses how management plans can be personalized to best support patient outcomes.
IBAT trial updates confirm efficacy and safety for PFIC patients
Further findings on the efficacy and safety of ileal bile acid transporter inhibitors for patients with progressive familial intrahepatic cholestasis have been presented at the 2024 AASLD The Liver Meeting in San Diego, California, USA.
Whole-exome sequencing sheds light on unexplained adult-onset cholestatic liver disease
Whole-exome sequencing led to definitive diagnoses for almost a quarter of patients with unexplained adult-onset cholestatic liver disease, say Italian researchers.
PFIC trial updates continue to support IBAT inhibitor efficacy and safety
Professor Richard Thompson shares his PFIC poster findings on the long-term efficacy and safety data of the PEDFIC 2 trial and the relationship between serum bile acid and event-free survival in the MARCH and MARCH-ON trials.
ABCB11 variants increase susceptibility to anabolic steroid-induced liver injury
Alterations to ABCB11 play a “pivotal role” in the development of drug-induced liver injury from anabolic steroids, US researchers reported at the 2024 AASLD The Liver Meeting in San Diego, California, USA.
EASL guidelines direct genetic cholestatic liver management
An EASL expert panel has developed clinical practice guidelines for the management of progressive familial intrahepatic cholestasis and other genetic cholestatic liver diseases.
Navigating Challenges in PBC Management: Focus on Inadequate Responders and Symptomatic Itching
In this case study module, Marlyn Mayo discusses 3 short patient profiles to illustrate difficult situations when treating patients with PBC including managing inadequate response to initial therapy and symptomatic itching.
Coping with PBC: treatment challenges and QoL insights
Kris Kowdley meets with patient Sabrina Reeser as they discuss the patient experience of treatment for PBC, including treatment challenges, variability in doctor-patient communication and involvement in clinical trials.
ELATIVE trial shows pruritus benefits with elafibranor in PBC
ELATIVE trial results for pruritus show benefits for both severity and impact on the quality of life of patients with primary biliary cholangitis.
Walking the path of PBC: navigating symptoms and QoL
David Jones meets with patient and patient advocate Mo Christie as they discuss the patient experience for PBC, including the burden of the disease and its impact on quality of life, with special reference to the common, and commonly misunderstood symptom, itch.
The evolving landscape of PBC: new therapies and future directions
Kris Kowdley and David Jones share their insights on the evolving landscape of PBC, including new and upcoming therapy options, and how these may change practice for the disease.
Barriers and symptoms burden: the unmet needs in PBC
Drs Marlyn Mayo and Gideon Hirschfield discuss the unmet needs in PBC management, highlighting the significant burden that symptoms pose for patients, the importance of monitoring and a patient-centric management approach offering insights into what might lie ahead in 2024.
The Liver Meeting 2023 – updates to the current landscape
Dr Palak Trivedi joins Dr Gideon Hirschfield to explore pivotal insights from The Liver Meeting 2023. Together, they highlight crucial updates, unveil novel findings, and deliver a concise overview of the current landscape of PBC.
ELATIVE: Elafibranor shows treatment efficacy in patients with PBC
ELATIVE trial shows that elafibranor significantly improves biochemical response in patients with primary biliary cholangitis with anti-pruritic benefits.
Positive RESPONSE for seladelpar in patients with PBC
RESPONSE trial findings show seladelpar improves markers of disease activity and reduces pruritus in patients with primary biliary cholangitis.
